23 April 2020 | News
In September 2019, Insilico Medicine announced a $37 million round led by prominent biotechnology and AI investors
Hong Kong headquartered Insilico Medicine has announced that it has entered into a research collaboration with Boehringer Ingelheim to utilize Insilico's generative machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying potential therapeutic targets implicated in a variety of diseases.
Alex Zhavoronkov, founder, and CEO of Insilico Medicine said, "Insilico Medicine is very impressed with the Research Beyond Borders group at Boehringer Ingelheim capabilities in the search of potential drug targets. In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide. We are very happy to partner with such an advanced group.”
Dr. Weiyi Zhang, Head of External Innovation Hub, Boehringer Ingelheim Greater China said, "We believe that Insilico's exclusive Pandomics platform will provide huge boost to our ability to explore and identify drug targets. We look forward to using AI to significantly improve the drug discovery process and contribute to human health.”
In September 2019, Insilico Medicine announced a $37 million round led by prominent biotechnology and AI investors.
Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes.